Alpha Cognition Inc (TSE:ACOG) has released an update.
Alpha Cognition Inc. reports on their 2024 first quarter achievements, highlighting the progress of their Alzheimer’s drug, ALPHA-1062, which is under FDA review and poised for commercialization by late July. The company successfully completed a private placement financing of $8.45 million and advanced pre-clinical studies and manufacturing processes. Financials show a decrease in R&D expenses compared to the previous year, indicating a streamlined approach towards their drug development initiatives.
For further insights into TSE:ACOG stock, check out TipRanks’ Stock Analysis page.
